These effects can be abolished by peroxisome proliferator-activated receptor gamma (PPARG) antagonist, suggesting that n-3 PUFAs may affect adipose tissue browning through PPARG and thus improve NAFLD (Yang et al., 2021). This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.